BPC-157 Research Overview: Literature, Testing and COAs

BPC-157 is one of the most extensively studied synthetic research compounds in the published literature on tissue repair, cellular signaling, and angiogenic biology. First characterized in the gastric juice research of Sikiric and colleagues in the early 1990s, BPC-157 has since accumulated a substantial body of peer-reviewed experimental data spanning gastrointestinal, musculoskeletal, vascular, neurological, and connective tissue models. Its broad mechanistic profile — engaging nitric oxide signaling, VEGFR2-associated angiogenesis, gene expression modulation, and actin pathway dynamics — has made it one of the most consistently referenced compounds in laboratory research settings investigating cellular repair and tissue remodeling biology.

This page provides a complete research reference for investigators working with BPC-157. It covers the compound’s molecular characteristics, its mechanistic profile as documented in the published literature, the key experimental models and endpoints investigators have used in BPC-157 research, protocol design considerations, frequently asked questions from the research community, and how investigators can source BPC-157 at verified purity levels with full analytical documentation.

BPC-157 is supplied strictly for in vitro and laboratory research use only. Not for human consumption. Not for use in clinical or diagnostic procedures.

BPC-157 Molecular Profile

BPC-157 — Body Protection Compound 157 — is a synthetic pentadecapeptide consisting of 15 amino acids in the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a protein fragment originally isolated from human gastric juice, where it occurs as part of a larger protective protein complex. The molecular formula is C62H98N16O22, with a molecular weight of 1419.556 g/mol and a PubChem CID of 108101.

The proline-rich structure of BPC-157 contributes to several properties relevant to laboratory research. Its conformational rigidity — conferred by the high proline content — reduces susceptibility to proteolytic degradation, supporting stability in aqueous experimental environments over extended periods. This stability characteristic distinguishes BPC-157 from many other research peptides that require more stringent handling conditions to maintain structural integrity during experimental protocols.

BPC-157 is produced via solid-phase peptide synthesis and supplied as a lyophilized powder. Each lot at Synagenics undergoes analytical verification using high-performance liquid chromatography and mass spectrometry to confirm molecular identity and purity prior to release. Batch-specific certificates of analysis from an independent third-party lab are available for every production run.

BPC-157 Research: Mechanistic Profile

The published BPC-157 research literature documents mechanistic activity across several well-characterized biological pathways. Understanding these mechanisms is essential for investigators designing experimental protocols and selecting appropriate endpoints for BPC-157 research studies.

Nitric Oxide Pathway Modulation

One of the most consistently reported mechanisms in BPC-157 research involves its influence on the nitric oxide signaling system. Published studies have described BPC-157’s interaction with the Src-Caveolin-1 signaling axis, which regulates endothelial nitric oxide synthase (eNOS) compartmentalization and activity within endothelial cells. Caveolin-1 normally inhibits eNOS by binding directly to the enzyme within caveolae membrane domains. BPC-157 research has documented disruption of this inhibitory interaction, with downstream effects on eNOS activity, nitric oxide production, and vascular endothelial function in experimental models.

The implications of this mechanism extend across multiple research domains. Nitric oxide pathway modulation influences vascular tone, endothelial permeability, platelet aggregation dynamics, and the initiation of angiogenic signaling cascades. Published BPC-157 research has examined each of these downstream effects across a range of experimental tissue systems, making NO pathway modulation one of the compound’s most broadly relevant mechanistic signatures in the research literature.

VEGFR2 Signaling and Angiogenesis Research

BPC-157 research has consistently documented influence on vascular endothelial growth factor receptor 2 (VEGFR2) expression and signaling. VEGFR2 is the primary signaling receptor for VEGF-A, the dominant pro-angiogenic growth factor in mammalian biology. Experimental data from BPC-157 studies describe increased VEGFR2-associated signaling following compound exposure in cellular models, with downstream effects on endothelial cell migration, proliferation, and tubular organization — the three cellular behaviors that collectively constitute angiogenic sprouting.

This VEGFR2 mechanism positions BPC-157 as a relevant research tool for investigators studying vascular biology, tissue perfusion, wound repair biology, and ischemic tissue models. Published BPC-157 angiogenesis research has measured endpoints including endothelial cell migration speed in scratch assays, capillary formation in matrigel assays, vascular density in tissue sections, and VEGFR2 expression levels by immunohistochemistry and western blot analysis.

Gene Expression Modulation: Egr, Nos, Vegf, and Srf

BPC-157 research has documented influence on the expression of multiple genes directly relevant to tissue repair and cellular signaling biology. Published studies have described changes in early growth response (Egr) gene expression, nitric oxide synthase (Nos) transcription, vascular endothelial growth factor (Vegf) expression, and serum response factor (Srf) activity following BPC-157 exposure in experimental models.

The Srf pathway is of particular mechanistic interest in BPC-157 research because of its role as a master regulator of cytoskeletal gene expression. Srf controls the transcription of actin and actin-binding proteins — placing BPC-157’s gene-level activity directly upstream of the cytoskeletal dynamics that govern cellular migration, morphology, and mechanical behavior. This connection between BPC-157’s Srf-mediated effects and actin biology has informed combination research designs pairing BPC-157 with TB-500, which engages the actin pathway at the protein sequestration level downstream of transcription.

Growth Hormone Receptor Upregulation in Fibroblasts

A mechanistically significant finding in the BPC-157 research literature involves its influence on growth hormone (GH) receptor expression in fibroblast models. Published studies have described BPC-157-associated upregulation of GH receptor density on fibroblast cell surfaces, with functional implications for fibroblast responsiveness to endogenous growth hormone signaling during experimental tissue repair protocols.

Fibroblasts with increased GH receptor expression demonstrate enhanced proliferative capacity, extended functional lifespan, and increased extracellular matrix production in growth hormone-supplemented research environments. This mechanism is relevant to investigators designing tissue repair research protocols where fibroblast activity is a primary variable, and informs the mechanistic rationale for BPC-157 and TB-500 combination research examining whether TB-500’s actin-mediated cytoskeletal support amplifies the effects of BPC-157’s GH receptor upregulation on fibroblast behavior.

FAK-Paxillin Focal Adhesion Signaling

BPC-157 research has described influence on focal adhesion kinase (FAK) and paxillin signaling — a pathway central to cellular attachment, migration, and cytoskeletal anchoring. Focal adhesions are the molecular anchors that connect the intracellular actin cytoskeleton to the extracellular matrix. FAK and paxillin coordinate the assembly and disassembly of these anchors during cell migration, controlling the speed and directionality of cellular movement through tissue environments.

Published BPC-157 studies examining FAK-paxillin pathway activity have documented phosphorylation changes consistent with enhanced focal adhesion dynamics — an effect that would functionally support the fibroblast and endothelial cell migration findings reported across multiple BPC-157 experimental models. This pathway provides a mechanistic bridge between BPC-157’s gene-level effects on actin production and its observed influence on cellular migration behavior in experimental systems.

Cytoprotective and Organoprotective Biology

A defining characteristic of BPC-157 research across tissue systems is the compound’s documented cytoprotective profile. Published research originating from the Sikiric laboratory at the University of Zagreb has described BPC-157’s capacity to maintain and reestablish tissue integrity across multiple organ systems in experimental injury models — a property characterized as organoprotection, extending the classical concept of gastroprotection to a broader range of tissue types.

This cytoprotective profile has been documented in gastrointestinal, hepatic, vascular, musculoskeletal, and neurological experimental models. The mechanistic basis for this broad cytoprotective activity is understood to involve BPC-157’s simultaneous engagement of multiple repair-relevant pathways — NO signaling, VEGFR2-mediated angiogenesis, gene expression modulation, and FAK-paxillin focal adhesion dynamics — rather than a single target-specific mechanism.

BPC-157 Experimental Models and Research Applications

BPC-157 research has been conducted across a wider range of experimental tissue models than almost any other synthetic research compound of comparable molecular size. Understanding the model systems in which BPC-157 has been studied helps investigators select the most relevant experimental context for their research questions.

Gastrointestinal Research Models

BPC-157 was originally characterized in gastrointestinal research, where it was studied for its influence on gastric mucosal integrity, esophageal tissue models, intestinal anastomosis biology, and fistula repair in rodent experimental systems. Published research in this area established BPC-157’s fundamental cytoprotective mechanistic profile and its stability in gastric juice environments — a property that distinguishes it from many other research peptides.

Musculoskeletal and Connective Tissue Research

BPC-157 research has been extensively conducted in tendon, ligament, muscle, and bone experimental models. Published studies have examined BPC-157’s influence on fibroblast outgrowth, tendon cell survival, and cellular migration in tendon injury models. Collagen organization, tensile strength recovery, and histological tissue architecture have been measured as endpoints in musculoskeletal BPC-157 research across multiple published studies.

Vascular and Cardiovascular Research Models

The VEGFR2 and NO pathway mechanisms of BPC-157 have driven substantial research interest in vascular biology applications. Published BPC-157 research has examined vascular recruitment, endothelial cell protection, thrombosis models, and cardiac tissue biology in experimental systems. The compound’s influence on vascular tone and endothelial function has been studied in both normal and injury-state vascular models.

Neurological Research Models

BPC-157 research has expanded significantly into neurological experimental models, examining the compound’s influence on dopaminergic signaling, serotonergic pathway interactions, and neuroprotective biology in rodent systems. Brain-gut axis research has examined BPC-157’s bidirectional influence on gastrointestinal and central nervous system signaling, reflecting the compound’s gastric origin and its documented activity in both peripheral and central experimental systems.

Designing a BPC-157 Research Protocol

Investigators designing laboratory research protocols incorporating BPC-157 should consider several practical variables that influence experimental outcomes and reproducibility.

Concentration Selection

Published BPC-157 research has employed a wide range of concentrations across different experimental model systems. Concentration selection should be guided by the published literature for the specific tissue model and endpoint under investigation. BPC-157 has been studied at nanogram to microgram per kilogram ranges in published animal model research, and at nanomolar to micromolar concentrations in cell culture experimental systems. Researchers should consult the referenced literature for concentration parameters specific to their model.

Exposure Timing and Duration

The temporal dynamics of BPC-157’s mechanistic effects vary across experimental systems and endpoints. Published research has examined both acute single-exposure designs and chronic multi-day administration protocols. Endpoint selection should align with the expected temporal profile of the mechanism under investigation — angiogenic endpoints typically require longer observation windows than acute cellular migration assessments.

Endpoint Selection and Measurement

BPC-157 research endpoints documented in the published literature include cellular migration speed and directionality in scratch and transwell assays, VEGFR2 expression by immunohistochemistry and western blot, eNOS activity and NO production measurements, histological tissue organization scores, tensile strength measurements in musculoskeletal models, and gene expression profiling for Egr, Nos, Vegf, and Srf targets. Endpoint selection should be mechanistically aligned with the research question and the model system selected.

Storage and Handling

BPC-157 is supplied as a lyophilized powder and should be stored at -20°C or below for long-term preservation. Repeated freeze-thaw cycles should be avoided to maintain compound integrity across experimental time points.

Frequently Asked Questions: BPC-157 Research

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide — a 15-amino acid sequence — derived from a protein fragment originally isolated from human gastric juice. Its full name is Body Protection Compound 157. It is studied in laboratory research for its influence on nitric oxide pathway modulation, VEGFR2-associated angiogenic signaling, gene expression modulation, and cellular migration dynamics in experimental tissue models. All research use is strictly in vitro and laboratory-based.

What purity standard is required for BPC-157 research use?

The accepted research-grade purity standard for BPC-157 is over 99% as confirmed by high-performance liquid chromatography on a per-batch basis. Mass spectrometry molecular identity confirmation — matching the observed molecular weight against the theoretical molecular weight of the 15-amino acid sequence — should accompany HPLC data. Both analytical data points should be available in a batch-specific certificate of analysis from an independent accredited laboratory before purchase.

What is the molecular weight of BPC-157?

The molecular weight of BPC-157 is 1419.556 g/mol. Its molecular formula is C62H98N16O22. The PubChem Compound ID is 108101. These parameters can be used to verify mass spectrometry confirmation data in certificates of analysis — the observed molecular weight in MS data should match the theoretical molecular weight within accepted analytical tolerance.

How should BPC-157 be stored for research use?

BPC-157 should be stored as a lyophilized powder at -20°C or below for long-term preservation. Dry peptides are stable at room temperature for short periods but should be returned to cold storage promptly. Avoid repeated freeze-thaw cycles, which can compromise compound integrity and affect experimental reproducibility.

Where can researchers source BPC-157 after PeptideSciences.com closed?

Following the closure of PeptideSciences.com in March 2026, researchers sourcing BPC-157 for ongoing protocols have been evaluating alternative suppliers against the same documentation criteria. Synagenics supplies BPC-157 with over 99% HPLC purity, mass spectrometry molecular identity confirmation, and batch-specific COA documentation from an independent accredited analytical laboratory. Full documentation is available before purchase.

Is BPC-157 available in capsule form for research use?

BPC-157 is available in capsule form at Synagenics for researchers requiring encapsulated compound for specific experimental designs. Capsules are provided exclusively as inert containers for the dry transport, storage, and handling of laboratory research materials. They are not dosage forms and are supplied strictly for research use only.

Does Synagenics ship BPC-157 to Canada?

Yes. BPC-157 ships to Canada from Synagenics’ Port St. Lucie, Florida facility. Domestic U.S. and Canada shipping options are confirmed at checkout. Bitcoin and credit card are both accepted as payment methods.

Key Published References for BPC-157 Research

• Sikiric P et al., “Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157: Vascular Recruitment and Gastrointestinal Tract Healing,” Current Pharmaceutical Design, 2018; 24(18): 1990–2001. View on PubMed →
• Sikiric P et al., “Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in Heart Disturbances,” Biomedicines, 2022; 10(11): 2696. View on PubMed →
• Hsieh M-J et al., “Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway,” Scientific Reports, 2020; 10(1): 17078. View on PubMed →
• Chang C-H et al., “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration,” Journal of Applied Physiology, 2011; 110(3): 774–780. View on PubMed →
• Sikiric P et al., “Stable Gastric Pentadecapeptide BPC 157 and Wound Healing,” Frontiers in Pharmacology, 2021; 12: 627533. View on PubMed →
• Huang T et al., “Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro,” Drug Design, Development and Therapy, 2015; 9: 2485–2499. View on PubMed →
• Sikiric P et al., “Pleiotropic Beneficial Activity of BPC 157 and Its Possible Relations with Neurotransmitter Activity,” Pharmaceuticals, 2024; 17(4): 461. View on PubMed →
• Drmic D et al., “Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157,” World Journal of Gastroenterology, 2018; 24(48): 5462–5476. View on PubMed →

Source BPC-157 for Your Research Protocol

BPC-157 is available at Synagenics with over 99% HPLC-verified purity, mass spectrometry molecular identity confirmation, and batch-specific certificates of analysis from an independent third-party lab. Ships from Port St. Lucie, Florida. Canada shipping available. Bitcoin and credit card accepted at checkout. Researchers combining BPC-157 with TB-500 in combination protocols can also source the BPC-157 + TB-500 Blend directly.

All products are supplied strictly for in vitro and laboratory research use only. Not for human consumption. Not for use in clinical or diagnostic procedures. These statements have not been evaluated by the Food and Drug Administration.